Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

BACKGROUND: Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Fa'ak, Faisal, Buni, Maryam, Falohun, Adewunmi, Lu, Huifang, Song, Juhee, Johnson, Daniel H, Zobniw, Chrystia M, Trinh, Van A, Awiwi, Muhammad Osama, Tahon, Nourel Hoda, Elsayes, Khaled M, Ludford, Kaysia, Montazari, Emma J, Chernis, Julia, Dimitrova, Maya, Sandigursky, Sabina, Sparks, Jeffrey A, Abu-Shawer, Osama, Rahma, Osama, Thanarajasingam, Uma, Zeman, Ashley M, Talukder, Rafee, Singh, Namrata, Chung, Sarah H, Grivas, Petros, Daher, May, Abudayyeh, Ala, Osman, Iman, Weber, Jeffrey, Tayar, Jean H, Suarez-Almazor, Maria E, Abdel-Wahab, Noha, Diab, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277540/
https://www.ncbi.nlm.nih.gov/pubmed/37328287
http://dx.doi.org/10.1136/jitc-2023-006814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277540/
https://www.ncbi.nlm.nih.gov/pubmed/37328287
http://dx.doi.org/10.1136/jitc-2023-006814

Ejemplares similares